• Nenhum resultado encontrado

BCR-ABL1

Expressão de microRNAs em células Bcr-Abl1 positivas: associação com a resistência...

Expressão de microRNAs em células Bcr-Abl1 positivas: associação com a resistência...

... oncogene bcr-abl1 que codifica a proteína Bcr-Abl1 com constitutiva atividade de tirosinoquinase ...de Bcr-Abl determina a leucemogênese por meio da alteração da adesão das células ...

96

Leucemia mielóide crônica atípica bcr-abl negativa: uma revisão integrativa de literatura / Atypical chronic myeloid leukemia bcr-abl1 negative: an integrative review

Leucemia mielóide crônica atípica bcr-abl negativa: uma revisão integrativa de literatura / Atypical chronic myeloid leukemia bcr-abl1 negative: an integrative review

... Introduction: Atypical Chronic Myeloid Leukemia(aCML) is a hematological neoplasia that is part of a greater group of disorders known as Myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) created by the WHO ...

22

Low expression of miR-196b enhances the expression of BCR-ABL1 and HOXA9 oncogenes in chronic myeloid leukemogenesis.

Low expression of miR-196b enhances the expression of BCR-ABL1 and HOXA9 oncogenes in chronic myeloid leukemogenesis.

... reduced BCR-ABL1 and HOXA9 protein levels (Figure ...restored BCR-ABL1 and HOXA9 protein levels (Figure 3A), enhanced cell proliferation ...of BCR-ABL1, by specific siRNAs, ...

8

A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia

A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia

... of BCR-ABL1 with tyrosine kinase inhibitors (TKIs) or small interfering RNA (siRNA) has been demonstrated to be an efficient targeted therapy for CML in the chronic phase ...The BCR-ABL1 ...

6

Efeito do veneno bruto e da L-aminoácido oxidase de Bothrops pirajai em células BCR-ABL...

Efeito do veneno bruto e da L-aminoácido oxidase de Bothrops pirajai em células BCR-ABL...

... neogene bcr-abl1 que codifica a oncoproteína BCR-ABL com alta atividade de ...leucêmica BCR-ABL + apresenta baixa adesão ao estroma medular, resistência à apoptose e potencial mitogênico ...TK ...

88

Expressão de DIDO em células Bcr-Abl+: associação com resistência a apoptose e fisiopatologia...

Expressão de DIDO em células Bcr-Abl+: associação com resistência a apoptose e fisiopatologia...

... de Bcr-Abl, c-Abl e proteínas fosforiladas nas linhagens foi realizada por ...de BCR-ABL1 e de DIDO 2 e entre índice de Sokal dos pacientes e expressão de DIDO ...linhagens BCR-ABL1 ...

117

Rev. Bras. Hematol. Hemoter.  vol.39 número3

Rev. Bras. Hematol. Hemoter. vol.39 número3

... The European Leukemia Net recommends RQ-PCR to deter- mine the BCR-ABL1 transcript level on the international scale every three months until a major molecular response (MMR – BCR-ABL ≤ 0.1%, or ...

2

Gold nanoparticles for nanotheranostics in leukemia – Addressing Chronic Myeloid Leukemia

Gold nanoparticles for nanotheranostics in leukemia – Addressing Chronic Myeloid Leukemia

... CML, BCR-ABL1 induces the deregulation of cell proliferation with the inhibition of apoptosis and an increased survival ...e14a2 BCR-ABL1 ...e14a2 BCR-ABL1 transcript was ...

220

Rev. Bras. Hematol. Hemoter.  vol.30 suppl.2

Rev. Bras. Hematol. Hemoter. vol.30 suppl.2

... the BCR-ABL kinase inhibitor, imatinib mesylate (Gleevec®, Novartis) led to significant changes in the treatment of chronic myeloid leukaemia (CML) ...second-generation BCR-ABL inhibitors nilotinib ...

6

Otimização das condições de pré-redução do As(V) em extratos do método BCR para quantificação de arsênio por HG-AAS.

Otimização das condições de pré-redução do As(V) em extratos do método BCR para quantificação de arsênio por HG-AAS.

... the BCR (French acronym for Community Bureau of Reference) method for the sequential extraction of As in ...the BCR extraction steps, different conditions of pre-reduction enabled the quantitative detection ...

10

Rev. Bras. Hematol. Hemoter.  vol.39 número2

Rev. Bras. Hematol. Hemoter. vol.39 número2

... Due to failure of tyrosine kinase inhibitor treatment and the negative BCR-ABL results, imatinib was ceased and hydroxyurea restarted with cellularity control. During the hospital stay, the dyspnea worsening and a ...

5

Lack of bcr and abr promotes hypoxia-induced pulmonary hypertension in mice.

Lack of bcr and abr promotes hypoxia-induced pulmonary hypertension in mice.

... Of the various cytokines that are generated downstream of the phosphorylation and activation of the p38 pathway, IL-6 was recently highlighted because of its important role in pulmonary vascular remodeling and pulmonary ...

12

Kinase protein: structural features and chemical inhibitors.

Kinase protein: structural features and chemical inhibitors.

... ABL- Abelson tirosina quinase; AML – leucemia mielóide aguda; AMPc - adenosina monofosfato cíclico; ATP - adenosina trifosfato; BCR – região do ponto de quebra ( breakpoint cluster reg[r] ...

10

Coexistance of JAK2V617F mutation and BCR/ABL translocation in one patient

Coexistance of JAK2V617F mutation and BCR/ABL translocation in one patient

... enlargement, 7,12 under imatinib mesylate treatment led some physicians to detect for JAK2 mutation in either peripheral blood or bone marrow. Probably, imatinib therapy suppresses the BCR-ABL clone, enabling the ...

3

Int. braz j urol.  vol.40 número3

Int. braz j urol. vol.40 número3

... All statistical analyses were completed using SPSS v. 19 software (SPSS Inc, IBM Corp, Somers, NY, USA). Cox univariate and multivari- ate regression models were carried out to identify variables for predicting ...

8

Identification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemias.

Identification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemias.

... the BCR-ABL translocation (Table ...in BCR-ABL+ ALL xenograft derived patient cells (Figure 4 and Table ...two BCR-ABL+ patient-derived cells with the T315I mutation (B003 and B004) were included in ...

11

Susceptibility of Ph-positive all to TKI therapy associated with Bcr-Abl rearrangement patterns: a retrospective analysis.

Susceptibility of Ph-positive all to TKI therapy associated with Bcr-Abl rearrangement patterns: a retrospective analysis.

... are BCR/ABL transcripts and TKI administration significantly influence mortality, and BCR/ABL transcripts, HSCT, and TKI administration are associated with the occurrence of ...(P50.004). BCR/ABL ...

14

Leucemia Mielóide Crônica: causas de falha do tratamento com mesilato de imatinibe.

Leucemia Mielóide Crônica: causas de falha do tratamento com mesilato de imatinibe.

... tência hematológica primária e secundária é rara em pacien- tes em fase crônica precoce e ocorre em 2%-4% dos pacien- tes. Já a resistência citogenética primária pode ocorrer em 15%-25% e está relacionada à capacidade de ...

5

Rev. Bras. Hematol. Hemoter.  vol.33 número6

Rev. Bras. Hematol. Hemoter. vol.33 número6

... Dasatinib (Sprycel®, Bristol-Myers Squibb) is a multi- target inhibitor of BCR-ABL tyrosine kinase, SRC family kinases, platelet-derived growth factor (PDGF) and c-kit receptors. It acts on the adenosine ...

6

J. Braz. Chem. Soc.  vol.13 número3

J. Braz. Chem. Soc. vol.13 número3

... are presented in Table 5. The in-set variations were determined using the propagation of errors, where the standard deviation of an individual solution (n = 3) propagate throughout the sub-samples of the extraction ...

7

Show all 73 documents...

temas relacionados